The cabinet does not have a winner’s shelf
A comparison is useful when it exposes a mismatch. These research records are not a league table.
The three labels
I’m not scoring these compounds for “healing power.” There is no common human trial here that would support that competition. The comparison starts with the material, because an impressive result for a neighbour is still a result for a neighbour.
| Compound | Original material and setting | The gap that matters |
|---|---|---|
| GHK-Cu | Copper-bound tripeptide; collagen cultures and small topical skin studies. | The skin barrier and the preparation tested limit the claim. |
| TB-500 | Seven-amino-acid fragment; much of the relevant literature used full thymosin beta-4. | Full-protein data do not establish fragment efficacy. |
| BPC-157 | Synthetic gastric fragment; a broad animal record with very little human work. | Three human pilots leave large controlled trials missing. |
GHK-Cu has the clearest human topical footing of this set. That describes its record rather than an all-purpose preference for the compound.
Which preparation did each study test?
The GHK-containing hair trial used a combination with 5-aminolevulinic acid. The healthy-volunteer thymosin-beta-4 trial used the full protein. The BPC-157 pharmacokinetic figures came from rats and dogs. None can be transferred intact to a differently named preparation or a different species.
For that reason, I’d put preparation identity at the centre of the comparison. The apparent hierarchy changes once the label becomes precise. A human study sounds stronger than an animal study, but a human study of the wrong substance cannot answer the fragment’s question. A combination outcome cannot assign the whole effect to one ingredient.
A positive result still has a particular job
Collagen production, neurological function after a rat stroke and blood-flow recovery in injured rat muscle are different outcomes. They matter within their respective experiments. They are not interchangeable measurements of how well a person’s injury will heal.
I’d accept a less sweeping conclusion in exchange for a reproducible result with a clear identity. The sports-medicine review describes the shortage of rigorous human safety data for unapproved peptides, while the BPC-157 review calls for larger trials. Those specific gaps leave the animal findings intact.
Drug approval is a separate matter. None of these has FDA approval as a drug; the cosmetic history of Copper Tripeptide-1 does not alter that. TB-500 and BPC-157 are prohibited in sport. The compound pages carry the fuller arguments, and the reading list retains the papers behind them.